|
|
 Previous Article | Table of Contents | Next Article 
Predictors of Long-Term Response to High-Dose Interferon Therapy in Type II Cryoglobulinemia Associated With Hepatitis C Virus Infection
Milvia Casato,
Vincent Agnello,
Leopoldo P. Pucillo,
Glenn B. Knight,
Marco Leoni,
Savino Del Vecchio,
Cristina Mazzilli,
Guido Antonelli, and
Lorenzo Bonomo
From the Departments of Clinical Medicine, Experimental Medicine and Pathology and Virology, University of Rome "La Sapienza," Ospedale Fatebenefratelli, San Pietro, Rome; Department of Biomedicine, University of Pisa, Italy; Department of Laboratory Medicine, Lahey Hitchcock Medical Center, Burlington; and the Edith Nourse Rogers Memorial Veterans Affairs Hospital, Bedford, MA.
We have prospectively studied patients with type II cryoglobulinemia since 1985 to assess the efficacy of treatment with interferon- at cumulative doses ranging from 234 to 849 MU. In the present study we retrospectively evaluated in this cohort parameters associated with complete response to therapy in 31 consecutive patients with type II cryoglobulinemia associated with hepatitis C virus (HCV) infection. Prevalence of complete response of cryoglobulinemia (disappearance of symptoms and signs of vasculitis and decrease of cryocrit below 10% of the initial value) was 62%, with a median response duration of 33 months and a range of 3 to 100 months. Three patients were putatively cured, as they remained in complete remission for more than 5 years off therapy. Eighteen patients (58%) had liver disease evidenced by histopathology and/or raised transaminase levels. Prevalence of normalization of transaminase levels was 100%, with a median response duration of 36 months. Relapse of hypertransaminasemia occurred in 100% and 8% of patients receiving less than or greater than 621 MU, respectively. By logistic regression analysis, the only pretherapy parameter that associated significantly (P = .0393) with complete response of cryoglobulinemia was the solitary anti-C22 (HCV core) antibody pattern, which was observed in 29% of patients. Association with older age and low cryocrit approached statistical significance (P = .06), while no significant correlations were found with serum IgM levels, duration of disease, HCV genotype, NS5a gene mutations, liver histology, HLA-DR phenotype, or WA cross-idiotype. Complete responses were also associated, on univariate statistical analysis, with low pretherapy HCV viremia. Responses were accompanied by decrease of viremia, of anti-HCV antibody levels and cryocrit. The usefulness of a high dose regimen is underscored by the higher rates of sustained responses of cryoglobulinemia and transaminase levels compared with previous studies.
Blood, Vol. 90 No. 10 (November 15), 1997:
pp. 3865-3873
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
F. G. DE ROSA and V. AGNELLO
Observations on Cryoglobulin Testing: I. The Association of Cryoglobulins Containing Rheumatoid Factors with Manifestation of Cryoglobulinemic Vasculitis
J Rheumatol,
September 1, 2009;
36(9):
1953 - 1955.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. G. DE ROSA, G. ABEL, and V. AGNELLO
Observations on Cryoglobulin Testing: II. The Association of Oligoclonal Mixed Cryoglobulinemia with Cirrhosis in Patients Infected with Hepatitis C Virus
J Rheumatol,
September 1, 2009;
36(9):
1956 - 1957.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Saadoun, D. A. Landau, L. H. Calabrese, and P. P. Cacoub
Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation
Rheumatology,
August 1, 2007;
46(8):
1234 - 1242.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Bianchettin, C. Bonaccini, R. Oliva, A. Tramontano, A. Cividini, M. Casato, G. Merlini, E. Silini, and M. U. Mondelli
Analysis of Hepatitis C Virus Hypervariable Region 1 Sequence from Cryoglobulinemic Patients and Associated Controls
J. Virol.,
May 1, 2007;
81(9):
4564 - 4571.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Carbonari, E. Caprini, T. Tedesco, F. Mazzetta, V. Tocco, M. Casato, G. Russo, and M. Fiorilli
Hepatitis C Virus Drives the Unconstrained Monoclonal Expansion of VH1-69-Expressing Memory B Cells in Type II Cryoglobulinemia: A Model of Infection-Driven Lymphomagenesis
J. Immunol.,
May 15, 2005;
174(10):
6532 - 6539.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. Aljurf, T. W. Owaidah, A. Ezzat, E. Ibrahim, and A. Tbakhi
Antigen- and/or immune-driven lymphoproliferative disorders
Ann. Onc.,
November 1, 2003;
14(11):
1595 - 1606.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ramos-Casals, O. Trejo, M. Garcia-Carrasco, and J. Font
Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infection
Rheumatology,
July 1, 2003;
42(7):
818 - 828.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Zaja, S. De Vita, C. Mazzaro, S. Sacco, D. Damiani, G. De Marchi, A. Michelutti, M. Baccarani, R. Fanin, and G. Ferraccioli
Efficacy and safety of rituximab in type II mixed cryoglobulinemia
Blood,
May 15, 2003;
101(10):
3827 - 3834.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Mazzaro, D'A. Little, G. Pozzato, L. A. Emens, M. S. Sulkowski, V. Agnello, C. Mecucci, M. Casato, F. Lefrere, X. Troussard, et al.
Regression of Splenic Lymphoma after Treatment of Hepatitis C Virus Infection
N. Engl. J. Med.,
December 26, 2002;
347(26):
2168 - 2170.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Casato, C. Mecucci, V. Agnello, M. Fiorilli, G. B. Knight, C. Matteucci, L. Gao, and J. Kay
Regression of lymphoproliferative disorder after treatment for hepatitis C virus infection in a patient with partial trisomy 3, Bcl-2 overexpression, and type II cryoglobulinemia
Blood,
March 15, 2002;
99(6):
2259 - 2261.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Jayne
Evidence-based treatment of systemic vasculitis
Rheumatology,
June 1, 2000;
39(6):
585 - 595.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ramos-Casals, O. Trejo, M. Garcia-Carrasco, R. Cervera, and J. Font
Mixed cryoglobulinemia: new concepts
Lupus,
February 1, 2000;
9(2):
83 - 91.
[Abstract]
[PDF]
|
|
|
|
|
|
|
O M CROSBIE and G J M ALEXANDER
Cryoglobulinaemia in HCV infection: coming in from the cold
Gut,
July 1, 1999;
45(1):
8 - 9.
[Full Text]
|
|
|
|
|
|
|
P Cresta, L Musset, P Cacoub, L Frangeul, D Vitour, T Poynard, P Opolon, D-T Nguyen, F Golliot, J-C Piette, et al.
Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus
Gut,
July 1, 1999;
45(1):
122 - 128.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. E. Reed, A. E. Gorbalenya, and C. M. Rice
The NS5A/NS5 Proteins of Viruses from Three Genera of the Family Flaviviridae Are Phosphorylated by Associated Serine/Threonine Kinases
J. Virol.,
July 1, 1998;
72(7):
6199 - 6206.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Casato, B. Lagana, L. P. Pucillo, and I. Quinti
Interferon for Hepatitis C Virus-Negative Type II Mixed Cryoglobulinemia
N. Engl. J. Med.,
May 7, 1998;
338(19):
1386 - 1387.
[Full Text]
|
|
|
|
|
